An open-label, active-controlled, parallel-group, single site Phase 1 study in healthy volunteers with flexible design
Latest Information Update: 17 Jan 2023
At a glance
- Drugs Debio 4126 (Primary) ; Debio 4126 (Primary) ; Octreotide
- Indications Acromegaly; Neuroendocrine tumours
- Focus Adverse reactions
- Acronyms Debio 4126-101
Most Recent Events
- 17 Jan 2023 New trial record
- 01 Sep 2022 Interim results published in 20th Congress of the European NeuroEndocrine Association.